Comparison of changes in blood pressure measurements and antihypertensive therapy in older, hypertensive, ambulatory care patients prescribed celecoxib or rofecoxib

Comparison of changes in blood pressure measurements and antihypertensive therapy in older, hypertensive, ambulatory care patients prescribed celecoxib or rofecoxib

Nietert P J; Ornstein S M; Dickerson L M; Rothenberg R J

Pharmacotherapy

2003

2003-11

Study Objective. To determine if changes in blood pressure and changes in class or dosing of antihypertensive drugs were significantly different in patients treated with celecoxib versus rofecoxib, two cyclooxygenase (COX)-2 inhibitors. Design. Retrospective cohort study. Setting. Thirty-one ambulatory care practices that shared an electronic medical record. Patients. Nine hundred sixty men and women over age 55 years with stable hypertension. Intervention. Patients had to have at least a 30-day supply of celecoxib or rofecoxib (any dose) prescribed between July 1, 1999, and June 30, 2000. Measurements and Main Results. Patients were followed for 6 months, and logistic regression and survival models were used to compare outcomes between groups while adjusting for confounders. Baseline characteristics of 517 patients receiving celecoxib and 443 receiving rofecoxib were similar. No significant differences were observed, regardless of the COX-2 inhibitor prescribed, in the proportion of patients whose systolic blood pressure increased by 20 mm Hg, whose diastolic blood pressure increased by 15 nun Hg, or who were prescribed a new class of antihypertensive drug. Compared with patients taking celecoxib, those taking rofecoxib were significantly more likely (odds ratio 1.68, 95% confidence interval 1.09-2.60) to have had the dosage of their antihypertensive drug increased and also the dosage increased sooner (p<0.05). New-onset cardiac and renal comorbidity, number of physician visits, and changes in body weight and laboratory values were not significantly different between the groups. Conclusion. No significant differences in blood pressure changes or in the proportion of patients who were prescribed a new class of antihypertensive drug were found between rofecoxib- and celecoxib-treated patients. However, significantly more rofecoxib-treated patients had the dosage of their existing antihypertensive drug increased compared with those receiving celecoxib.

congestive-heart-failure; controlled trial; cox-2 inhibitor; elderly-patients; gastrointestinal toxicity; nonsteroidal antiinflammatory drugs; nsaids; osteoarthritis; Pharmacology & Pharmacy; renal-function; rheumatoid-arthritis

Journal Article

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

1416-1423

11

23